Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Equities

603896

CNE100002XJ4

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-05 pm EDT 5-day change 1st Jan Change
27.56 CNY +0.22% Intraday chart for Zhejiang Shouxiangu Pharmaceutical Co., Ltd. +1.40% -14.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.(XSSC:603896) added to S&P Global BMI Index CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million. CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shouxiangu Pharma Unit Secures Re-Registration Approval for Three Drugs MT
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020. CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 4, 2020, has expired with 3,585,000 shares, representing 2.5% for CNY 165.08 million. CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020. CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020. CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020. CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020. CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. announces an Equity Buyback for 3,600,000 shares, for CNY 216 million. CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Xu Meiyun completed the acquisition of 5.99% stake in Zhejiang Shouxiangu Pharmaceutical Co., Ltd. from Zhejiang Shouxiangu Investment Management Co., Ltd. CI
Chart Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
More charts
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a China-based company principally engaged in the breeding, cultivation, processing and sales of traditional Chinese medicinal materials, such as the ganoderma lucidums and dendrobium officinales. The Company's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The Company mainly operates its businesses in domestic markets through wholesaling and direct sales.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
27.56
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603896 Stock
  4. News Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
  5. Shouxiangu Pharma Unit Secures Re-Registration Approval for Three Drugs
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW